Cost-utility of tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in France: a multi-state Markov model analysis
Authors' conclusion
Our study represents the first assessment of the cost-effectiveness of tofacitinib in France and incorporates the latest adverse effects reported in the literature.
Study context
- Population
- Simulated patients with moderate-to-severe RA after MTX failure, Francesimulated cohort
- Participants
- 10,000 patients
- Exposure
- Strategies including tofacitinib at different introduction positions vs reference strategy of four biologic classes (TNFi, tocilizumab, abatacept, RTX)
- Outcome
- Cost-effectiveness (costs and QALYs) of introducing tofacitinib in second-line therapies
- Follow-up
- Lifetime
Methodological detailsmulti-state Markov model, simulated cohort based on literature data, 6-month cycles, lifetime horizon, one-way sensitivity analysis, Severe adverse effect data sourced from the ORAL Surveillance study
- Multi-state Markov model
- Simulated cohort based on literature data
- 6-month cycles
- Lifetime horizon
- One-way sensitivity analysis
- Severe adverse effect data sourced from the ORAL Surveillance study
Main finding
As reported in the abstract
Cost-effectiveness vs reference strategy
Tofacitinib as first-line treatment: cost savings per patient (greatest)
€1,679
Tofacitinib as first-line treatment: QALY increase
0.29
Observational data: associations, not effects.
Further findings
One-way sensitivity analysis
- Discount rate and cost of TNFi most influenced costs
- Change in HAQ score and discount rate most influenced quality-adjusted life years (QALYs)
Original publication
Cost-utility of tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in France: a multi-state Markov model analysis. Clin Exp Rheumatol. Published 15 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →